Sex Transm Dis by Crosby, Richard A. et al.
Community-Based Screening for Cervical Cancer: A Feasibility 
Study of Rural Appalachian Women
Richard A. Crosby, PhD1, Michael E. Hagensee, MD, PhD2, Robin Vanderpool, DrPH1, Nia 
Nelson, MS2, Adam Parrish, PhD(c)1, Tom Collins, BS1, and Nebraska Jones, RN1
1College of Public Health at the University of Kentucky
2Louisiana State University Health Sciences Center
Abstract
Objectives—To describe women’s comfort levels and perceptions about their experience self-
collecting cervico-vaginal swabs for HPV testing; to determine whether nurse-guided patient 
navigation increases the odds of women receiving a traditional Pap test after HPV screening; and 
to test the hypothesis that women testing positive for oncogenic HPV would be more likely to 
have a subsequent Pap test than those testing negative.
Methods—400 women were recruited from eight rural Appalachian counties, in 2013 and 2014. 
After completing a survey, women were provided instructions for self-collecting a cervico-vaginal 
swab. Specimens were tested for 13 oncogenic HPV types. Simultaneously, women were notified 
of their test results and offered initial navigation for Pap testing. Chart-verified Pap testing within 
the next six months served as the endpoint.
Results—Comfort levels with self-collection were high: 89.2% indicated they would be more 
likely to self-collect a specimen for testing, on a regular basis, compared to Pap testing. Thirty 
women (7.5%) had a follow-up Pap test. Women receiving added nurse-guided navigation efforts 
were significantly less likely to have a subsequent test (P = .01). Women testing positive for 
oncogenic HPV were no more likely than those testing negative to have a subsequent Pap test (P 
= .27). Data were analyzed in 2014.
Conclusions—Rural Appalachian women are comfortable self-collecting cervico-vaginal swabs 
for HPV testing. Further, efforts to re-contact women who have received an oncogenic HPV test 
result and an initial navigation contact may not be useful. Finally, testing positive for oncogenic 
HPV may not be a motivational factor for subsequent Pap testing.
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Cervical cancer mortality is preventable if women and their health care providers remain 
vigilant about following Pap-testing guidelines: cytology every 3 years from ages 21 
through 65.1 Although traditional, clinic-based Pap testing remains valuable,2,3 the Food and 
Drug Administration recently (April 2014) approved the cobas® Human Papillomavirus 
(HPV) Test (to detect HPV types 16 and 18) as an initial screening method.4 This approval 
creates an important opportunity, in that cervico-vaginal swabs can be self-collected 
allowing screening to occur in non-clinical settings. Ample evidence exists suggesting that 
self-collected swabs for HPV testing are comparably effective to clinician-collected 
samples.5–16 Studies of women who have self-collected cervico-vaginal swabs for HPV 
testing have concluded that self-collection is easy to perform, provides privacy, and is less 
embarrassing and more comfortable to women than physician collected 
samples.7–9,12,13,16,17–21 Evidence also supports the idea that use of self-collected swabs for 
HPV testing can become a valuable strategy for reaching underserved 
populations.5–9,12,14,16,18–21
Two behavioral research questions emerge from the new opportunities to reach women who 
may not be adherent to Pap screening guidelines. First, the question of whether patient 
navigation (assisting women, as needed, to complete all recommended steps in the medical 
care process) can be applied to women testing positive for oncogenic HPV via non-clinical 
testing (self-collected cervico-vaginal swabs) is vital. Given the present ability to have 
women self-collect cervico-vaginal swabs, making refinements in patient navigation for 
those tested in the community is now an important endeavor. Patient navigation programs 
are especially effective for increasing screening rates for breast and colorectal cancers.22–23 
Related to cervical cancer screening, recent interventions reveal that patients who receive 
navigation services self-report completing Pap testing at significantly higher levels than do 
control groups.24–25 However, self-reporting of Pap tests does not prove the validity of using 
self-testing for HPV DNA detection.26 Further, to our knowledge, only one study has been 
published regarding the use of self-collected cervico-vaginal swabs as a component of a 
navigation intervention.21 An obligation of testing women in non-clinical settings is the 
corresponding effort needed to bring those testing positive for oncogenic HPV to a clinic for 
Pap testing, colposcopy with directed biopsy, and possible treatment. Key issues to receiving 
screening and care related to cervical cancer among Appalachian women could include 
economic and environmental barriers that prevent regular Pap testing.21,28–29
The second behavioral question involves whether testing positive for an oncogenic HPV 
type may motivate women to seek clinical prevention services has not yet been addressed 
empirically. The purpose of this study was threefold: 1) to describe women’s comfort levels 
and perceptions about their experience of self-collecting cervico-vaginal swabs for HPV 
testing, 2) to determine whether nurse-guided patient navigation efforts increase the odds of 
women receiving a Pap test after being screened for HPV via self-collected swabs not 
collected in a clinical setting, and 3) to test the hypothesis that women testing positive for 
oncogenic strains of HPV would be more likely to have a subsequent Pap test than those 
testing negative.
Crosby et al. Page 2











A total of 441 women were invited to participate in the study. Of these, 41 refused yielding a 
participation rate of 90.7% and a sample size of 400. Recruitment occurred in eight 
economically distressed counties (as designated by the Appalachian Regional 
Commission)27 of rural Appalachian Kentucky from late 2013 through mid-year of 2014. 
Economic barriers include lack of health insurance or lack of the ability to cover co-
payments; whereas environmental barriers include issues such as transportation and 
childcare. Also, the selected area experiences one of the nation’s highest death rates from 
cervical cancer.30 Eligibility criteria were: 1) being between 30–65 years of age, 2) reporting 
not having a Pap test in the past three years, and 3) reporting not currently being pregnant, 4) 
reporting never testing positive for HPV, 5) reporting sexual activity in the past 12 months. 
Women under 30 years of age were not included because HPV testing is not recommended 
as a screening strategy.1 Recruitment flyers were posted in all seven of the regionalized local 
health departments comprising the district. Women were also recruited personally at 
community outreach events and non-traditional healthcare settings (e.g., mental health and 
substance use treatment clinics). Recruitment occurred from September of 2013 through 
April of 2014.
Procedures
All study procedures were approved by the Office of Research Integrity at the University of 
Kentucky. Only female research assistants were employed. Women completed a paper-and-
pencil survey instrument prior to receiving instructions for specimen collection. Survey 
questions collected demographic and health information, as well as attitudes toward sexual 
health and HPV in particular. Next, a research assistant read aloud a specimen collection 
instruction sheet, before providing a hard copy to each woman. Women took the instructions 
into a public or private restroom (depending upon recruitment venue). After self-collecting, 
women then swirled the collection brush 40 times in a specimen vial containing 
Preservecyt®, a fixing solution. They then sealed the specimen vial, placed it in a pre-
labeled bag, and returned the sealed bag to a research assistant. Upon returning the 
specimens, women completed a post-survey regarding their self-collection experience. 
Women received $20 to compensate their time. Samples were stored in a temperature-
controlled environment (30°F or −1°C) until they were shipped on dry ice to a third-party 
laboratory (Louisiana State University Health Science Center).
Research nurses native to the catchment area provided results to women via their indicated 
method of choice (i.e. phone or face-to-face) within 1–2 weeks of receiving the results from 
the laboratory. Regardless of the HPV test results, all women were offered navigation to 
traditional Pap testing services. Navigation included offering assistance with scheduling 
examinations, transportation and childcare services, and attending appointments with 
women. Women testing positive for oncogenic HPV were provided with detailed 
information on HPV and its link to cervical cancer; informed that their risk of developing or 
having cervical cancer was elevated; and that follow-up Pap testing was an important means 
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of detecting any cervical abnormalities. Navigation efforts also included assistance in 
obtaining colposcopy when indicated by a provider.
All women were re-contacted 1-month after the initial navigation attempt. Women who self-
reported receiving Pap tests answered questions regarding the date and location of services, 
as well as results if they were known. Verification of results occurred via chart review. 
Women who reported not having completed Pap testing 1-month after receiving HPV results 
were again offered navigation. This process was repeated a final time for women who 
remained unscreened three months after receiving their results. Navigation assistance was 
offered to all women receiving results. Most women had received medical services through 
the local county health departments. Women lacking insurance or having no income they 
were informed of the Women’s Cancer Screening program available through their county 
health department (a program providing services free or on a sliding scale). It was 
emphasized to women with positive test results that if they qualified the Women’s Cancer 
Screening Program that they would be eligible for further treatment following an abnormal 
Pap, if needed.
Self-Reported Measures
Several likely covariates were measured relative to the analysis of the nurse-guided patient 
navigation efforts and whether women testing HPV-positive were more likely to have Pap 
tests. First, a 6-item scale (developed by the authors) assessed women’s perceptions of 
fatalism regarding cervical cancer. Items were: 1) “Getting cervical cancer is beyond my 
control,” 2) “If I am supposed to get cervical cancer, there is nothing I can do to prevent it,” 
3) “The odds are that women in the [8-county catchment area] will get cervical cancer,” 4) 
“Getting cervical cancer is a matter of bad luck,” 5) “If I get cervical cancer I cannot control 
my odds of survival,” and 6) “The odds are low that a women in the [8-county catchment 
area] will survive cervical cancer.” The scale produced a marginally acceptable inter-item 
reliability coefficient (Cronbach’s alpha = .692). Higher scores represented a greater degree 
of fatalism. Second, a question asked: “Have you ever had a Pap test? (note, a Pap test is 
done to detect early signs of cervical cancer).” In addition, the following covariates were 
assessed: intent to have a Pap test if testing positive for HPV, whether women did test 
positive for oncogenic HPV, age, marital status, and whether women reported a monthly 
household income of less than $1,000.
Laboratory Analysis
HPV was detected by Polymerase Chain Reaction (PCR) analysis. Cellular DNA was 
extracted from the self-collected swabs using a Qiagen DNA extraction kit. The DNA was 
extracted from BSC cells as an extraction control with every 20 samples.31 HPV DNA was 
amplified and genotyped using the Roche reverse line blot system.31,32 This assay utilized 
the extended-spectrum and biotin-labeled L1 consensus (PGMY09/11, amplicon 450 bp) 
and biotin-labeled β-globin primers (PC04, GH20, amplicon 250 bp). Specimen samples 
demonstrating the 450 bp L1 amplicon were genotyped using the 37 types contained on the 
reverse line blot: the 13 high-risk HPV types were defined as 16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, and 68. Any bands that were more intense than the low β-globin band 
intensity were scored as positive.
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To test the nurse-guided patient navigation efforts and whether women testing HPV-positive 
were more likely to have Pap tests, chi-squared analyses were used, followed by the 
construction of two multivariable logistic regression models. In both models, the outcome 
variable was whether women had a Pap test subsequent to HPV testing. The first model 
regressed the variable capturing second navigation contacts on the assessed covariates as 
well as whether women tested positive for oncogenic HPV. The second model regressed 
whether women tested positive for oncogenic HPV on the covariates. Data were analyzed in 
2014, using SPSS (version 20.0). Significance was defined by an alpha-level of .05
Results
Average age of the sample was 40.2 years (standard deviation=9.3 years). The majority 
reported their race was White (93.8%), with 2.8% identifying as Black and the remainder 
identifying as other races. The majority (59.3%) reported a monthly household income of 
less than $1,000. Only 5.3% reported a monthly household income exceeding $5,000. The 
mean number of children living with women was 1.09 (standard deviation=1.19), with 
41.5% indicating that no children currently lived in their household. Other descriptive 
characteristics are shown in Table 1.
Women’s Experience in Self-Collecting Swabs
Because the consent process included the point that women would be asked to self-collect a 
cervico-vaginal swab, the study was not designed to describe or quantify the refusal to self-
collect. The majority (97.5%) of the 400 women who enrolled in the study reported that they 
understood the directions they were given for self-collection of the cervico-vaginal 
specimen. When asked “how comfortable were you with collecting the specimen,” 41.9% 
selected the option of “comfortable,” 17.8% selected “somewhat comfortable,” 16.8% 
selected “slightly comfortable,” 17.3% selected “neither comfortable nor uncomfortable,” 
and 5.5% selected “uncomfortable.” About 18% (18.5) reported experiencing some pain 
during the collection process, and 10.5% reported bleeding during the collection process. A 
majority (89.2%) reported they would you be more likely to do this test on a regular basis 
compared to having Pap tests. Finally, in responding to a question asking for level of 
agreement regarding whether women would have a Pap test or colposcopy “if my HPV test 
is positive”, 55.9% selected the response option of “strongly agree”, with 26.6% selecting 
“agree,” 8.5% selecting “slightly agree,” and the remainder selecting a level of 
disagreement. For subsequent analyses, this measure was dichotomized to compare those 
indicating “strongly agree” (an optimal measure of intent) to the remaining 44.1% of the 
women.
Nurse-Guided Navigation Success
Of the 400 enrolled women, all were successfully contacted to receive their results and 
immediately offered navigation assistance. Of these 400, 264 (66.0%) were successfully 
contacted for a second navigation attempt (beyond the initial attempt that occurred when 
women were informed of their test result). Also, 30 (7.5%) received a chart-verified Pap test 
within six months of study enrollment. None of the women received colposcopy. In a cross-
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tabulation of these two variables, 12.5% of the women who did not receive the second 
navigation contact had a subsequent Pap test, compared with 4.9% for those who did receive 
this second contact (P = .006). Bivariate contrasts between having a chart-verified Pap test 
within six months of HPV testing and the selected covariates are shown in Table 1. As 
shown in this Table, none of the covariates obtained significance and the effect of testing 
positive for oncogenic HPV was not significant. Additionally, mean differences in age (not 
shown in Table 1) did not differ significantly between women having a Pap test (40.2 years) 
and those not (41.4 years) having a Pap test (t=.73, df=398, P=.46).
In a multivariable logistic regression model controlling for the influence of age, marital 
status, a household income of less than $1,000 per month, intent to have a Pap test, testing 
positive for oncogenic HPV, and the 6-item measure of cervical cancer fatalism, the adjusted 
odds ratio for the navigation variable was .36 (95% CI=.16–.80), indicating significantly 
lower odds of having a Pap test for women receiving a second navigation effort. None of the 
covariates were significant in this model (Table 2).
Effect of Testing HPV-Positive
Overall, 31.3% of the women tested positive for oncogenic HPV. More specifically, 15.8% 
tested positive of one HPV type and 15.5% tested positive for two or more types. Chi-
squared analysis indicated no differences in subsequent Pap testing between women testing 
negative (n=275, 68.7%), those testing positive for one type (n=63, 15.7%), and those 
testing positive for two or more types (n=62, 15.5%). Thus, the two groups of women testing 
positive were collapsed into one (this was done because women were only told whether they 
tested positive or negative thus a behavioral effect of testing positive for two or more strains 
could not have occurred).
As shown in Table 1, a significant association between testing positive for HPV and having 
a subsequent Pap test was not found (P=.33). Of the 125 women testing positive for one or 
more strains of HPV, 5.6% had a chart-verified Pap test in the next six months. In contrast, 
of the 275 women testing negative, 8.4% had a chart-verified Pap test. Although this 50% 
difference favored women testing negative, it was not statistically significant.
To test whether the selected covariates would influence this non-significant bivariate 
association, the second multivariable logistic regression model was constructed (this model 
excluded the variable representing the second navigation contact). As shown in Table 3, the 
effect of testing positive was not significantly associated with subsequent Pap testing after 
removing the variable representing the second navigation contact and after controlling for 
the assessed covariates.
Finally, whether testing positive for oncogenic HPV moderated the significant association 
between a second navigation contact and subsequent Pap testing was investigated by a 
layered chi-squared test. A moderating effect did occur, with the association between 
navigation and Pap testing being significant only for women testing negative for HPV. 
Among women testing negative and not receiving a second navigation contact, 13.7% had a 
chart-verified Pap test compared to 5.2% of those testing negative and receiving a second 
contact (P=.014). Conversely, among women testing positive and not receiving a second 
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navigation contact, 8.8% had a chart-verified Pap test compared to 4.4% of those testing 
positive and receiving a second contact (P=.34).
Discussion
With some exceptions, women were physically comfortable with the process for self-
collecting cervico-vaginal swabs for HPV testing and 89% preferred this method of 
screening over traditional, clinic-based Pap testing. Although this finding suggests the utility 
of non-clinical screening for medically underserved women, the findings pertaining to the 
second and third study purposes did not support the study hypotheses. Rather than being 
predictive of having a subsequent Pap test, those receiving a second navigation contact were 
significantly less likely to have a chart-verified Pap test within six months. This finding 
suggests that multiple navigation attempts may not increase the chances of having a Pap test. 
The counter-intuitive finding may simply be a consequence of the idea that second attempts 
were made for women who already rejected the initial navigation, meaning that these 
women had already decided against a Pap test. More specifically, women who are motivated 
by receiving an HPV test result and an initial navigation contact promoting a Pap test will do 
so without having to be re-contacted and those who are re-contacted will be unlikely to have 
a Pap test. This effect, however, was significantly magnified for women testing negative for 
oncogenic HPV thereby suggesting a need for further investigations designed to determine 
women’s psychosocial responses to an HPV-negative test result. Regardless of why HPV 
status moderates the relationship, it is vital to emphasize that women testing positive were 
not significantly more likely than those testing negative to have a follow-up Pap exam. This 
latter finding strongly suggests that simply notifying women of HPV-positive test results 
may not be enough; instead navigation efforts should emphasize Pap testing to women 
testing positive for oncogenic HPV. This emphasis may need to take the form of a brief, 
intensive, tailored education session that can be delivered efficiently by phone.
That only 7.5% of the women received a Pap test within six months of having the HPV test 
suggests that a simple linkage between non-clinical HPV testing and the receipt of clinical 
services may not exist for rural Appalachian women. Data from these women suggest that 
clinical services may not be reaching some women, especially given that 87 of the 400 
women had never had a Pap test (mean age=40.5 years, standard deviation=9.8 years). Of 
the 313 women who reported ever having a Pap test, the estimated mean number of year-
intervals between tests was 3.6 years (standard deviation=5.3), well over the recommended 
intervals. Thus, constructing “bridges” that lead under-served women into clinical care is an 
important priority for rural Appalachian women.23,24
The fact that none of the assessed covariates achieved significance with the outcome of 
having a chart-verified Pap test was surprising. Thus, the apparent lack of access and/or 
complacency about a follow-up Pap test may occur for rural Appalachian women regardless 
of marital status, low-income status, whether they have ever had a Pap test, and their age. 
Further, although fatalism about cervical cancer was common in this sample, women were 
equally unlikely to have a follow-up Pap test regardless of whether this fatalism was high. 
This suggests that a “life-saving” type of behavioral intervention program may be 
ineffective. Finally, it is intriguing to note that women’s expressed intent to have a follow-
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up Pap test, if they tested positive for oncogenic HPV, had no meaningful bearing on 
whether this actually occurred. In a post-hoc analysis of just the women testing positive for 
oncogenic HPV, we observed that 7.7% of those stating this intent had a chart-verified Pap 
test compared to 2.1% of those not stating this intent (P=.19). Although not statistically 
significant, this post-hoc analysis of only 125 women was clearly underpowered given that 
only seven received a Pap test. Further investigation is warranted.
Limitations
Findings are limited by the use of a convenience sample. Also, the study design could not 
determine whether motivational issues or access issues operated to preclude Pap testing. For 
instance, women may have been motivated to have a Pap test as a consequence of being 
tested for HPV, but they may have perceived a lack of access to these services (despite our 
navigation attempts). In addition, our selection of covariates was limited; clearly 
unmeasured confounding may have occurred. For instance, we did not assess women’s 
health insurance status or their past use of healthcare services. Also, it must be noted that 
women were selected for this sample based on lack of Pap testing in the past three years, 
thereby precluding generalization to all rural Appalachian women. Finally, the very low 
numbers of women having a chart-verified Pap test created an unanticipated lack of 
statistical power for the study.
Conclusions
Findings suggest that optimizing community-based screening for cervical cancer among 
rural Appalachian women will require substantial linkages to clinical care. A key challenge 
will be navigating oncogenic HPV-positive women who do not seek Pap testing once this 
test result is provided to them. Health communication interventions should be created that 
educates and persuades women testing oncogenic HPV-positive to seek Pap testing.
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Table 1
Bivariate Associations with Having a Pap Test After Being Screened for HPV via Self-Collection of a 
Cervico-Vaginal Swab (N = 400)
Correlate % Having Pap Test P
Second navigation occurred
  No (n = 136) 12.5
  Yes (n = 264) 4.9 .006
Tested positive for oncogenic HPV
  No (n = 275) 8.4
  Yes (n = 125) 5.6 .33
Covariates
Scored higha on fatalism for cervical cancer
  No (n = 222) 8.6
  Yes (n = 171) 5.8 .31
Ever had a Pap test
  No (n = 82) 7.3
  Yes (n = 313) 7.7 .91
Married
  No (n = 216) 6.0
  Yes (n = 180) 9.4 .37
Household income > $1,000 per month
  No (n = 237) 5.9
  Yes (n = 163) 9.8 .14
Intend to have Pap test if HPV test is positive
  No (n = 177) 6.2
  Yes (n = 223) 8.5 .38
a
The distribution for this construct was dichotomized by a median split
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Table 2
Association of Second Navigation, and Assessed Covariates, with Having a Pap Test After Being Screened for 
HPV via Self-Collection of a Cervico-Vaginal Swab (N = 400)
Outcomes AORa 95% CIb P
Second navigation occurred .36 .16–.80 .01
Age 1.01 .97–1.05 .69
Married 1.00 .97–1.03 .79
Household income > $1,000 per month 1.53 .70–3.36 .28
Intend to have Pap test if HPV test is positive 1.55 .67–3.59 .31
Tested positive for oncogenic HPV 1.65 .63–4.35 .31
Scored highc on fatalism for cervical cancer 1.50 .66–3.42 .34




The distribution for this construct was dichotomized by a median split
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Table 3
Association of Testing Positive for Oncogenic HPV, and Assessed Covariates, with Having a Pap Test After 
Being Screened for HPV via Self-Collection of a Cervico-Vaginal Swab (N = 400)
Outcomes AORa 95% CIb P
Tested positive for oncogenic HPV 1.71 .66–4.44 .27
Age 1.01 .97–1.06 .52
Married 1.00 .97–1.03 .80
Household income > $1,000 per month 1.78 .81–3.91 .15
Intend to have Pap test if HPV test is positive 1.69 .73–3.88 .22
Scored highc on fatalism for cervical cancer 1.46 .65–3.31 .36




The distribution for this construct was dichotomized by a median split
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